NEWARK, N.J., Aug. 12 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. (“BioNeutral”) , a specialty chemical technology-based Life Science company announced today that ATS Labs using the EPA required AOAC Sporicidal Test with Ygiene(TM) Hospital Grade formula delivered a 100% Total Kill of over one million live Clostridium Sporogenes spores in a four (4) minute time frame - performance which is up to 75 times faster than competitive products such as Steris(R) Spor-Klenz RTU.
“Whether it is the present Swine Flu (H1N1) pandemic or the most difficult to kill dangerous organisms, Bioneutral’s technology has given rise to the only family of sporicidal formulations for the hospital/health care sector, industry (including schools) and the home. Performance is unsurpassed, it has a Green environmental profile, is non corrosive, non staining to most fabrics (eg sheets and pillow cases) and can come into contact with skin while remaining sporicidal,” said Dr Andy Kielbania PhD, BioNeutral’s Chief Scientific Officer.
Examples of commonly used antimicrobials in health care facilities which cannot claim passing this EPA sporicide/sterilant test include CaviCide(R) and Medica DC 10(TM). While these antimicrobials may eliminate easily eradicated bacteria and some viruses, they have no effect on spores and therefore cannot claim to be sporicidal. Examples of antimicrobials which have passed the EPA required test include Actril(R) Cold Sterilant and Clidox(R)(R)-S which require hours to be effective. Steris(R) Hydrogen Peroxide Sterilant requires special protective equipment and highly trained professionals to correctly apply this antimicrobial. In addition this product requires 90 minutes of direct contact to eliminate spores. Steris(R) Spor-Klenz RTU is easier to apply but can take up to five and one half hours (5.5 hours) to eliminate spores.
About ATS Labs:
About BioNeutral Group, Inc.
More information about the Company may be found at www.bioneutralgroup.com
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company’s technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company’s data and findings. BioNeutral’s antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
SOURCE BioNeutral Group, Inc.
CONTACT: Stephen J. Browand, President and CEO of BioNeutral Group Inc.,
steve@bioneutralgroup.com; or Investor Relations, Aimee Boutcher,
+1-973-239-2878, aboutcher@aol.com
Web site: http://www.bioneutralgroup.com/
